Cargando…

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer

OBJECTIVE: Oligometastatic prostate cancer is a limited metastatic disease state in which potential long-term control is still possible with the use of targeted therapies such as surgery or stereotactic body radiation therapy (SBRT). SBRT may as well potentially prolong the time before the initiatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azzam, Gregory, Lanciano, Rachelle, Arrigo, Steve, Lamond, John, Ding, William, Yang, Jun, Hanlon, Alexandra, Good, Michael, Brady, Luther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419680/ https://www.ncbi.nlm.nih.gov/pubmed/26000249 http://dx.doi.org/10.3389/fonc.2015.00101

Ejemplares similares

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
por: Bernetich, Matthew, et al.
Publicado: (2014)

Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
por: Ricco, Anthony, et al.
Publicado: (2020)

Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting
por: Heal, Cory, et al.
Publicado: (2015)

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
por: Hasan, Shaakir, et al.
Publicado: (2015)

Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy
por: Hasan, Shaakir, et al.
Publicado: (2016)

Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature
por: Ahmad, Shaharyar, et al.
Publicado: (2017)

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2012)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations
por: Ricco, Anthony, et al.
Publicado: (2020)

Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database
por: Ricco, Anthony, et al.
Publicado: (2017)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
por: Wegner, Rodney E., et al.
Publicado: (2019)

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer
por: Mohan, Riche, et al.
Publicado: (2023)

SBRT treatment of abdominal and pelvic oligometastatic lymph nodes using ring‐mounted Halcyon Linac
por: Pokhrel, Damodar, et al.
Publicado: (2021)

Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study
por: Katz, Alan Jay, et al.
Publicado: (2014)

Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses
por: Patel, Nisha R., et al.
Publicado: (2014)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

Prostate Fiducial Marker Placement in Patients on Anticoagulation: Feasibility Prior to Prostate SBRT
por: Iocolano, Michelle, et al.
Publicado: (2020)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Locoregional control and survival after lymph node SBRT in oligometastatic disease
por: Loi, Mauro, et al.
Publicado: (2018)

Dose-Escalated Robotic SBRT for Stage I–II Prostate Cancer
por: Meier, Robert
Publicado: (2015)

Editorial: Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate
por: Vargo, John A., et al.
Publicado: (2015)

Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer
por: Adorno Febles, Victor R., et al.
Publicado: (2020)

Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist's Point of View
por: Stelcer, Ewelina, et al.
Publicado: (2019)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
por: Mercier, Carole, et al.
Publicado: (2022)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival
por: Yarchoan, Mark, et al.
Publicado: (2015)

Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments
por: Navarria, Pierina, et al.
Publicado: (2014)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
por: Fuller, Donald Blake, et al.
Publicado: (2020)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
por: Gerum, Sabine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_maceb5mbruf6os6hdn2805r877